# Contribution of Dolutegravir to Obesity and Cardiovascular Disease

> **NCT04340388** · PHASE4 · COMPLETED · sponsor: **Augusta University** · enrollment: 10 (actual)

## Conditions studied

- HIV-1-infection
- Antiviral Drug Adverse Reaction
- Vascular Diseases
- Cardiovascular Abnormalities
- Abnormality of Adipose Tissue
- Body Weight Changes
- Body Fat Disorder
- HIV-Associated Lipodystrophy Syndrome

## Interventions

- **DRUG:** Dolutegravir 50 MG
- **DRUG:** Antiretroviral/Anti HIV

## Key facts

- **NCT ID:** NCT04340388
- **Lead sponsor:** Augusta University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-17
- **Primary completion:** 2022-06-17
- **Final completion:** 2023-02-25
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2023-07-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04340388

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04340388, "Contribution of Dolutegravir to Obesity and Cardiovascular Disease". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04340388. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*